Evaluation and Management of Polycystic Ovary Syndrome
Diagnostic Evaluation
Diagnose PCOS using the Rotterdam criteria when a reproductive-age woman presents with at least two of the following three features: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. 1
Clinical Assessment
Menstrual history: Cycle length >35 days indicates chronic anovulation; persistent oligomenorrhea 2-3 years beyond menarche predicts ongoing menstrual irregularities and greater likelihood of PCOS. 2
Hyperandrogenism assessment: Look for hirsutism (gradual onset, intensifies with weight gain), acne (especially severe or treatment-resistant), and androgenic alopecia (vertex, crown, or diffuse pattern; bitemporal loss suggests severe hyperandrogenemia). 2
Rapid-onset virilization with clitoromegaly: This pattern suggests androgen-secreting tumor rather than PCOS and requires immediate ovarian and adrenal imaging. 3
Laboratory Workup
Free testosterone is more sensitive than total testosterone for establishing androgen excess and should ideally be measured through equilibrium dialysis techniques. 2
TSH and prolactin must be checked to exclude thyroid disease and hyperprolactinemia as alternate causes of oligomenorrhea and hyperandrogenism. 3
Overnight dexamethasone suppression test or 24-hour urinary free cortisol if signs of hypercortisolism are present to exclude Cushing's syndrome. 3
2-hour oral glucose tolerance test with 75-gram glucose load to screen for diabetes and glucose intolerance, as insulin resistance affects all PCOS phenotypes regardless of BMI. 3, 4
Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) because women with PCOS have elevated cardiovascular risk. 3
Imaging
Transvaginal ultrasound (if sexually active) should identify ≥25 follicles (2-9 mm) in the whole ovary or ovarian volume ≥10 mL using current ultrasound technology. 5
Ultrasound should NOT be used for diagnosis in adolescents <17 years because large multicystic ovaries are common normal findings in this age group. 2, 6
Follicle number per ovary (FNPO) is the gold standard ultrasonographic marker for polycystic ovarian morphology in adult women. 5
Additional Screening
Screen for depression, anxiety, body image concerns, and eating disorders (binge-eating disorder, night-eating syndrome), as these are highly prevalent in PCOS and dramatically reduce adherence to treatment. 4, 3
Calculate BMI and measure waist circumference using ethnic-specific cutoffs (lower thresholds for Asian, Hispanic, and South Asian populations who have heightened cardiometabolic risk). 4, 3
Management Strategy
First-Line Treatment for ALL Patients (Regardless of BMI)
Initiate multicomponent lifestyle intervention combining diet, exercise, and behavioral strategies as mandatory first-line therapy for all women with PCOS, because insulin resistance is present irrespective of BMI and affects both lean and overweight women. 4, 7
Dietary Intervention
Create a daily energy deficit of 500-750 kcal (target intake 1,200-1,500 kcal/day) for women with elevated BMI. 4, 7
No specific diet type is superior—any balanced dietary approach that respects patient preferences and cultural needs is acceptable, including low glycemic index, high-fiber, omega-3-rich, ketogenic, Mediterranean, or anti-inflammatory diets. 4
Target 5-10% weight loss in those with excess weight, as this yields significant improvements in insulin resistance, ovulation frequency, fertility, and reduces long-term endometrial cancer risk. 4, 7
For normal-weight women, focus on diet quality rather than caloric restriction while maintaining healthy eating principles. 4
Exercise Prescription
Prescribe ≥150 minutes/week of moderate-intensity activity OR ≥75 minutes/week of vigorous-intensity activity, performed in bouts of at least 10 minutes (approximately 1,000 steps per bout). 4, 7
Include muscle-strengthening activities involving major muscle groups on 2 non-consecutive days per week. 4, 7
For greater weight loss, increase to ≥250 minutes/week of moderate-intensity OR ≥150 minutes/week of vigorous-intensity activity. 4
Minimize sedentary behavior—reduce prolonged sitting, screen time, and overall sedentary time throughout the day. 4
Both aerobic and resistance exercise improve insulin sensitivity independent of weight loss. 4
Behavioral Strategies
Implement SMART goal-setting (Specific, Measurable, Achievable, Realistic, Timely) with self-monitoring using fitness-tracking devices for step count and exercise intensity. 4, 7
Start with realistic 10-minute activity bouts and progressively increase total activity by approximately 5% weekly. 4
Include comprehensive behavioral techniques: goal-setting, stimulus control, problem-solving, assertiveness training, slower eating, positive reinforcement, and relapse-prevention planning. 4, 7
Address psychological factors actively—refer patients with moderately severe depression to psychiatry or behavioral health for evaluation and potential pharmacotherapy, as depression dramatically reduces adherence to lifestyle interventions. 4
Monitoring Schedule
Fortnightly review for the first 3 months with structured dietary and physical activity plans. 3
Regular review for the first 12 months to ensure adherence and adjust interventions. 3
Regular monitoring of weight and waist circumference throughout both weight-loss and maintenance phases. 4, 3
Medical Management
For Women NOT Attempting to Conceive
Prescribe combined oral contraceptive pills (COCs) as first-line hormonal therapy because they suppress ovarian androgen secretion, increase sex hormone-binding globulin, regulate menstrual cycles, prevent endometrial hyperplasia, and reduce hirsutism and acne. 4, 3, 8
Typical dosing regimen: drospirenone 3 mg/ethinyl estradiol 20 μg in a 24-active/4-inert pill regimen, taken daily. 4
COCs reduce the risk of endometrial cancer and are associated with increases in circulating triglyceride and HDL cholesterol levels. 4
Add spironolactone (antiandrogen) as second-line therapy for persistent hirsutism or acne, as combined medical interventions (antiandrogen plus ovarian suppression) are most effective for hyperandrogenism. 4, 8
Metformin 500-2,000 mg daily should be added for patients with insulin resistance, glucose intolerance, or metabolic features, starting at 500 mg daily and titrating to 1,000-2,000 mg daily in divided doses. 4, 3
GLP-1 receptor agonists (liraglutide 1.8-3 mg daily, semaglutide 1-2 mg weekly, or exenatide 5-10 μg twice daily or 2 mg weekly) in combination with lifestyle interventions can improve weight loss and metabolic control. 4
For Women ATTEMPTING to Conceive
Prescribe letrozole as first-line pharmacological treatment for ovulation induction in women with PCOS attempting to conceive. 8, 9
Clomiphene citrate is an alternative first-line option, with approximately 80% of patients ovulating and 50% conceiving. 4, 8
Metformin 1 g twice daily for 12 weeks or until pregnancy can be used in the pregestational stage to improve fertility outcomes. 4
If clomiphene treatment fails, use low-dose gonadotropin therapy, which induces high rates of monofollicular development with lower risk of ovarian hyperstimulation. 4
Long-Term Monitoring and Prevention
Screen for type 2 diabetes with 2-hour oral glucose tolerance test, as PCOS confers elevated lifetime risk of metabolic syndrome and diabetes. 3, 10
Monitor cardiovascular risk factors regularly, as PCOS is now considered a cardiovascular disease risk-enhancing factor with increased risk of myocardial infarction and stroke even in reproductive years. 10
Screen for obstructive sleep apnea, which occurs more frequently in women with PCOS. 8
Provide endometrial protection through regular menstruation (at least every 3 months) to prevent endometrial hyperplasia and reduce the at least twofold increased risk of endometrial cancer. 8, 2
Ensure respectful, patient-centered interactions that avoid weight-related stigma, as this negatively impacts treatment engagement. 4
Special Considerations
Adolescents
Diagnosis requires BOTH irregular menstrual cycles (defined according to time postmenarche) AND clinical/biochemical hyperandrogenism following exclusion of other disorders. 6
Adolescents with only one feature should be considered "at risk" of PCOS and require symptom management and ongoing follow-up. 6
Do NOT use polycystic ovarian morphology on ultrasound or anti-Müllerian hormone levels for diagnosis during adolescence. 6
Prescribe ≥60 minutes/day of moderate-to-vigorous intensity physical activity, including muscle- and bone-strengthening activities at least 3 times weekly. 4
Prevention of weight gain and monitoring should begin from adolescence, as weight gain escalates from this period and central obesity increases progressively with age. 4
Lean/Normal-Weight Women
Do NOT dismiss lifestyle intervention in lean PCOS patients simply because they have normal BMI—insulin resistance requires management regardless of weight. 4
Focus on diet quality rather than caloric restriction for thin women, while maintaining the same exercise and behavioral strategy recommendations. 4
Multicomponent lifestyle programs lower fasting plasma glucose by approximately 0.8 mmol/L and reduce fasting insulin by about 13 mU/L even in women without obesity. 4
Lifestyle interventions reduce circulating total testosterone by approximately 0.5 nmol/L and increase sex hormone-binding globulin by approximately 20 nmol/L, improving the hormonal environment for ovulation regardless of baseline body weight. 4